Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure

Phase II Misses Could Benefit BMS’s Cobenfy

 
• By Joseph Haas
  
AbbVie exterior
AbbVie's emraclidine failed two Phase II studies in schizophrenia • Source: Alamy

More from Clinical Trials

More from Business